Amendment Statement of Principles concerning ACUTE MYELOID LEUKAEMIA (No. 17 of 2020)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.

Dated 28 February 2020

The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:

Professor Nicholas Saunders AO
Chairperson
## Contents

1. Name...................................................................................................................3
2. Commencement .................................................................................................3
3. Authority ..........................................................................................................3
4. Amendment .......................................................................................................3
1 **Name**

This is the Amendment Statement of Principles concerning *acute myeloid leukaemia* (No. 17 of 2020).

2 **Commencement**

This instrument commences on 23 March 2020.

3 **Authority**

This instrument is made under subsections 196B(2) and (8) of the *Veterans’ Entitlements Act 1986*.

4 **Amendment**

The Statement of Principles concerning *acute myeloid leukaemia* (No. 71 of 2015) (Federal Register of Legislation No. F2015L00903) is amended in the following manner:

<table>
<thead>
<tr>
<th>Section</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>9(13a)</td>
<td>Insert the following factor in subsection 9(13a): inhaling, ingesting or having cutaneous contact with dieldrin or aldrin for a cumulative period of at least 1 000 hours before the clinical onset of acute myeloid leukaemia, where the first exposure to dieldrin or aldrin occurred at least five years before the clinical onset of acute myeloid leukaemia;</td>
</tr>
<tr>
<td>9(13b)</td>
<td>Insert the following factor in subsection 9(13b): inhaling, ingesting or having cutaneous contact with diazinon for a cumulative period of at least 1 000 hours before the clinical onset of acute myeloid leukaemia, where the first exposure to diazinon occurred at least five years before the clinical onset of acute myeloid leukaemia;</td>
</tr>
</tbody>
</table>